Sky Labs, a South Korea-based medical technology company, announced on Monday that it has shared clinical research outcomes of its ring-type blood pressure monitor, CART, at ESC Congress 2026 in Munich, Germany.
Sky Labs hosted five dedicated sessions presenting new clinical data on atrial fibrillation (AF) and heart failure (HF) patients for the first time.
Professor Ki-Hong Lee (Chonnam National University Hospital) presented a 24-hour BP monitoring study on AF patients, stating: "Using the CART blood pressure monitor, we achieved an analysable data rate of approximately 80%, demonstrating the utility of ring-type 24-hour BP testing and enabling continuous observation of nocturnal dipping patterns."
Professor In-Cheol Kim (Keimyung University Dongsan Hospital) shared research on severe HF patients (mean EF 29%), noting: "A simultaneous comparison between the CART blood pressure monitor and conventional 24-hour ABPM demonstrated high agreement, fully meeting ESH error margin criteria." This confirms CART as a reliable tool for personalised HF treatment, Sky Labs said.
The CART blood pressure monitor enables continuous BP tracking even in AF and HF patients who previously faced measurement limitations with conventional cuffs due to irregular pulses or high variability.
THX Pharma secures European patent for Batten-1 in juvenile Batten disease
Orphalan commences Phase 3 study of trientine therapy in Wilson disease
ZAGENO named Frost & Sullivan's 2026 North American Life Sciences E-Commerce Company of the Year
Pharvaris reports Phase 3 success for deucrictibant XR in HAE prophylaxis
Sky Labs presents clinical research outcomes for ring-type blood pressure monitor CART
Etcamah–CDK4/6 inhibitor combination approved in US for ESR1-mutated HR-positive breast cancer
Ionis partner Novartis reports pelacarsen Phase 3 trial misses primary endpoint
Guardant Health wins FDA approval for Guardant360 CDx in advanced breast cancer
4basebio announces expansion of DNA offering for personalised mRNA medicines
Rznomics reports advances in high-efficiency circRNA production in Nucleic Acids Research
Kali Therapeutics' KT501 Investigational New Drug application cleared by US FDA
Thryv Therapeutics licenses new class of SGK1 inhibitors, expanding into neurodegenerative disease